Fumarate propofol tenofovir tablets (Vemlidy) are the core drug for the treatment of chronic hepatitis B, covering virus suppression, special population management, and long-term efficacy maintenance. They are suitable for adult and adolescent patient populations.

1. Core treatment scope

(1) Chronic hepatitis B virus infection: antiviral therapy suitable for patients aged 12 years and above with a body weight of ≥ 35kg.

(2) Compensatory liver disease: used for long-term viral suppression and disease control in patients with compensatory liver function.

2 Characteristics of applicable population

(1) HBV DNA positive patients: chronic hepatitis B infected patients with positive viral load test.

(2) Patients with a history of special treatment: including newly diagnosed patients and those who have poor response to other nucleoside analogue treatments.

3 Scope of treatment mechanisms

(1) Virus replication inhibition: Blocking virus replication by selectively inhibiting HBV DNA polymerase.

(2) Long term virus control: Continuous medication can maintain stable virological response and improve biochemical indicators.

4 Special management scope

(1) Renal function adjustment: Adjust the dosage based on creatinine clearance rate, especially for patients with renal insufficiency.

(2) Co infection management: HIV co infected individuals must cooperate with a complete antiretroviral therapy regimen.